| PMID |
|
|
| TITLE |
|
| Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. |
|
| ABSTRACT |
|
|
|
| The tissue-specific translation elongation factor eEF1A2 is a potential oncogene that is overexpressed in human ovarian cancer. eEF1A2 is highly similar (98%) to the near-ubiquitously expressed eEF1A1 (formerly known as EF1-alpha) making analysis with commercial antibodies difficult. We wanted to establish the expression pattern of eEF1A2 in ovarian cancer of defined histological subtypes at both the RNA and protein level, and to establish the mechanism for the overexpression of eEF1A2 in tumours. We show that while overexpression of eEF1A2 is seen at both the RNA and protein level in up to 75% of clear cell carcinomas, it occurs at a lower frequency in other histological subtypes. The copy number at the EEF1A2 locus does not correlate with expression level of the gene, no functional mutations were found, and the gene is unmethylated in both normal and tumour DNA, showing that overexpression is not dependent on genetic or epigenetic modifications at the EEF1A2 locus. We suggest that the cause of overexpression of eEF1A2 may be the inappropriate expression of a trans-acting factor. The oncogenicity of eEF1A2 may be related either to its role in protein synthesis or to potential non-canonical functions. |
|
| DATE PUBLISHED |
|
|
| HISTORY |
|
| PUBSTATUS |
PUBSTATUSDATE |
| aheadofprint |
2007/04/17 |
| pubmed |
2007/04/18 09:00 |
| medline |
2007/07/03 09:00 |
| entrez |
2007/04/18 09:00 |
|
| AUTHORS |
|
| NAME |
COLLECTIVENAME |
LASTNAME |
FORENAME |
INITIALS |
AFFILIATION |
AFFILIATIONINFO |
| Tomlinson VA |
|
Tomlinson |
V A L |
VA |
|
Medical Genetics, School of Molecular and Clinical Medicine, University of Edinburgh, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, UK. |
| Newbery HJ |
|
Newbery |
H J |
HJ |
|
|
| Bergmann JH |
|
Bergmann |
J H |
JH |
|
|
| Boyd J |
|
Boyd |
J |
J |
|
|
| Scott D |
|
Scott |
D |
D |
|
|
| Wray NR |
|
Wray |
N R |
NR |
|
|
| Sellar GC |
|
Sellar |
G C |
GC |
|
|
| Gabra H |
|
Gabra |
H |
H |
|
|
| Graham A |
|
Graham |
A |
A |
|
|
| Williams AR |
|
Williams |
A R W |
AR |
|
|
| Abbott CM |
|
Abbott |
C M |
CM |
|
|
|
| INVESTIGATORS |
|
|
| JOURNAL |
|
| VOLUME: 96 |
| ISSUE: 10 |
| TITLE: British journal of cancer |
| ISOABBREVIATION: Br. J. Cancer |
| YEAR: 2007 |
| MONTH: May |
| DAY: 21 |
| MEDLINEDATE: |
| SEASON: |
| CITEDMEDIUM: Print |
| ISSN: 0007-0920 |
| ISSNTYPE: Print |
|
| MEDLINE JOURNAL |
|
| MEDLINETA: Br J Cancer |
| COUNTRY: England |
| ISSNLINKING: 0007-0920 |
| NLMUNIQUEID: 0370635 |
|
| PUBLICATION TYPE |
|
| PUBLICATIONTYPE TEXT |
| Comparative Study |
| Journal Article |
| Research Support, Non-U.S. Gov't |
|
| COMMENTS AND CORRECTIONS |
|
| REFTYPE |
REFSOURCE |
REFPMID |
NOTE |
| Cites |
Nat Genet. 2002 Jul;31(3):301-5 |
12053177 |
|
| Cites |
J Biol Chem. 2002 Feb 15;277(7):5418-25 |
11724805 |
|
| Cites |
Cancer Res. 2002 Aug 15;62(16):4722-9 |
12183431 |
|
| Cites |
Nucleic Acids Res. 2001 May 1;29(9):e45 |
11328886 |
|
| Cites |
Clin Cancer Res. 2002 Dec;8(12):3933-42 |
12473609 |
|
| Cites |
Nat Genet. 2003 Jul;34(3):337-43 |
12819783 |
|
| Cites |
J Mol Med (Berl). 2003 Sep;81(9):536-48 |
12898041 |
|
| Cites |
Am J Pathol. 2004 May;164(5):1511-8 |
15111296 |
|
| Cites |
Mol Carcinog. 2004 Jul;40(3):171-9 |
15224349 |
|
| Cites |
J Biol Chem. 1992 Nov 25;267(33):24064-8 |
1385435 |
|
| Cites |
Eur J Biochem. 1993 Aug 1;215(3):549-54 |
8354261 |
|
| Cites |
Trends Biochem Sci. 1995 May;20(5):169-70 |
7610475 |
|
| Cites |
Genomics. 1996 Sep 1;36(2):359-61 |
8812466 |
|
| Cites |
J Cell Sci. 1996 Nov;109 ( Pt 11):2705-14 |
8937988 |
|
| Cites |
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4463-8 |
9539760 |
|
| Cites |
J Neuropathol Exp Neurol. 2005 Apr;64(4):295-303 |
15835265 |
|
| Cites |
BMC Cancer. 2005;5:113 |
16156888 |
|
| Cites |
Bioinformatics. 2005 Nov 1;21(21):4067-8 |
16141249 |
|
| Cites |
Anal Quant Cytol Histol. 2006 Feb;28(1):43-53 |
16566279 |
|
| Cites |
J Cell Biochem. 2007 Feb 1;100(2):267-78 |
16888816 |
|
| Cites |
Cancer Res. 2000 Oct 1;60(19):5405-9 |
11034080 |
|
| Cites |
Oncology. 2002;62(4):349-53 |
12138243 |
|
|
| GRANTS |
|
| GRANTID |
AGENCY |
COUNTRY |
|
Wellcome Trust |
United Kingdom |
|
| GENERAL NOTE |
|
|
| KEYWORDS |
|
|
| MESH HEADINGS |
|
| DESCRIPTORNAME |
QUALIFIERNAME |
| Adenocarcinoma, Clear Cell |
pathology |
| DNA Methylation |
pathology |
| Epigenesis, Genetic |
physiology |
| Female |
physiology |
| Gene Expression Profiling |
physiology |
| Gene Expression Regulation, Neoplastic |
physiology |
| HL-60 Cells |
physiology |
| HeLa Cells |
physiology |
| Humans |
physiology |
| Ovarian Neoplasms |
pathology |
| Peptide Elongation Factor 1 |
genetics |
| Tumor Cells, Cultured |
genetics |
|
| SUPPLEMENTARY MESH |
|
|
| GENE SYMBOLS |
|
|
| CHEMICALS |
|
| REGISTRYNUMBER |
NAMEOFSUBSTANCE |
| 0 |
EEF1A2 protein, human |
| 0 |
Peptide Elongation Factor 1 |
|
| OTHER ID's |
|
| OTHERID |
SOURCE |
| PMC2359942 |
NLM |
|
